Drug intelligence / Profile preview

ABS-002

Development stage: Preclinical
Lead developer: Alpha Biomedical
Modality: Stem Cell Therapies → Cell Therapies

Overview

ABS-002 is a mesenchymal stem cell (MSC) therapy under development by Alpha Biomedical for the treatment of osteoarthritis. Currently in the preclinical stage, the therapy leverages the regenerative and immunomodulatory properties of MSCs to address joint degeneration. MSCs are hypothesized to promote cartilage repair and reduce synovial inflammation through the secretion of paracrine factors and direct cell-to-cell interactions, potentially offering a disease-modifying approach for patients with osteoarthritis.

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on ABS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-002.

Explore the full profile